Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (MUSIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04484935 |
Recruitment Status :
Active, not recruiting
First Posted : July 24, 2020
Last Update Posted : November 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
RSV Infection | Drug: Nirsevimab | Phase 2 |
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) among infants and young children, resulting in annual epidemics in Japan. Children with congenital or acquired immunodeficiencies, transplant recipients, and those receiving immunosuppressive therapy are at increased risk for severe RSV-associated LRTI with prolonged viral shedding and higher viral loads, resulting in prolonged hospitalizations, admissions to the intensive care unit (ICU), and the need for mechanical ventilation. Palivizumab (Synagis®) is the only approved agent for RSV prophylaxis, and its half-life (t1/2) is approximately 1 month, infants and young children need to receive monthly intramuscular doses of palivizumab throughout the RSV season to maintain protection. This constitutes a significant burden on healthcare providers as well as the infants/children and their families.
Nirsevimab may provide a cost-effective opportunity to protect all infants from RSV disease based on an improvement in potency and the extended t1/2 that is expected to support once-per-RSV-season dosing.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Masking Description: | Open: no masking is used. All involved know the identity of the intervention assignment. |
Primary Purpose: | Prevention |
Official Title: | A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 Months of Age |
Actual Study Start Date : | August 19, 2020 |
Estimated Primary Completion Date : | February 23, 2023 |
Estimated Study Completion Date : | February 23, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Nirsevimab
1st RSV season: 50mg nirsevimab
|
Drug: Nirsevimab
Single fixed IM dose of nirsevimab 50 mg if body weight < 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
Other Name: Nirsevimab (MEDI8897) |
- Safety and tolerability of nirsevimab when administered to immunocompromised children ≤ 24 months of age [ Time Frame: Through 360 days post dose. ]All treatment-emergent adverse event (TEAEs), treatment-emergent serious adverse event (TESAEs), adverse event of special interest (AESIs), new onset chronic disease (NOCDs)
- To evaluate the PK of nirsevimab [ Time Frame: Through 360 days post dose. ]Summary of nirsevimab serum concentrations
- To evaluate ADA responses to nirsevimab in serum [ Time Frame: Through 360 days post dose. ]Incidence of ADA to nirsevimab in serum
- To assess the efficacy of nirsevimab when administered as a single intramuscular (IM) dose to infants ≤ 24 months of age [ Time Frame: Through 360 days post dose ]Incidence of medically attended lower respiratory tract infection (LRTI; inpatient and outpatient) and hospitalizations due to reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) through 150 days after administration of nirsevimab

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 0 Years to 2 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Neonate, infant, or young child ≤ 24 months of age at the time of dose administration who, per investigator judgement, are:
- In their first year of life AND entering their first RSV season at the time of dose administration OR
- In their second year of life AND entering their second RSV season at the time of dose administration
-
The subject must meet at least 1 of the following conditions at the time of informed consent.
- Diagnosed with combined immunodeficiency (severe combined immunodeficiency, X-linked hyper-immunoglobulin M [IgM] syndrome, etc); antibody deficiency (X linked agammaglobulinemia, common variable immunodeficiency, non-X-linked hyper-IgM syndromes, etc); or other immunodeficiency (Wiskott-Aldrich syndrome, DiGeorge syndrome, etc), or
- Diagnosed with human immunodeficiency virus infection, or
- History of organ or bone marrow transplantation, or
- Subject is receiving immunosuppressive chemotherapy, or
- Subject is receiving systemic high-dose corticosteroid therapy (prednisone equivalents ≥ 0.5 mg/kg every other day, other than inhaler or topical use), or
- Subject is receiving other immunosuppressive therapy (eg, azathioprine, methotrexate, mizoribine, mycophenolate mofetil, cyclophosphamide, cyclosporine, tacrolimus, cytokine inhibitors, etc)
- Written informed consent and any locally required authorization obtained from the subject's parent(s)/legal representative(s) prior to performing any protocol-related procedures, including screening evaluations.
- Subject's parent(s)/legal representative(s) able to understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.
- Subject is available to complete the follow-up period, which will be approximately 1 year after receipt of nirsevimab
Exclusion Criteria:
-
Subject who meets any of the palivizumab indications approved in Japan other than immunocompromised condition.
- Subject born at ≤ 28 weeks gestation and is ≤ 12 months of age
- Subject born at 29 to 35 weeks gestation and is ≤ 6 months of age
- Age ≤ 24 months with a history of bronchopulmonary dysplasia requiring medical management within the past 6 months
- Age ≤ 24 months with current hemodynamically significant congenital heart disease (CHD)
- Age ≤ 24 months with Down syndrome
- Requirement for oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, or other mechanical respiratory or cardiac support at screening
- A current, active infection, including RSV infection, at the time of screening or at the time of investigational product administration.
- Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or acute illness within 7 days prior to investigational product administration.
- Any serious concurrent medical condition (renal failure, hepatic dysfunction, suspected active or chronic hepatitis infection, seizure disorder, unstable neurologic disorder, etc), except those resulting in an immune deficiency condition.
- Clinically significant congenital anomaly of the respiratory tract.
- Receipt of palivizumab.
- Any known allergy or history of allergic reaction to any component of nirsevimab.
- Any known allergy or history of allergic reaction to immunoglobulin products, blood products, or other foreign proteins.
- Concurrent enrollment in another interventional study, or prior receipt of any investigational agent.
- Anticipated survival of less than 1 year at the time of informed consent.
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of study results.
- Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04484935
United States, California | |
Research Site | |
Los Angeles, California, United States, 90027 | |
United States, Florida | |
Research Site | |
Tampa, Florida, United States, 33606 | |
United States, New York | |
Research Site | |
Syracuse, New York, United States, 13210 | |
United States, South Carolina | |
Research Site | |
North Charleston, South Carolina, United States, 29406 | |
United States, Tennessee | |
Research Site | |
Memphis, Tennessee, United States, 38105 | |
United States, Texas | |
Research Site | |
Fort Worth, Texas, United States, 76104 | |
United States, Washington | |
Research Site | |
Tacoma, Washington, United States, 98405 | |
Belgium | |
Research Site | |
Bruxelles, Belgium, 1200 | |
Research Site | |
Liège, Belgium, 4000 | |
Japan | |
Research Site | |
Bunkyo-ku, Japan, 113-8519 | |
Research Site | |
Fuchu-shi, Japan, 183-8561 | |
Research Site | |
Kawasaki-shi, Japan, 216-8511 | |
Research Site | |
Kurume-shi, Japan, 830-0011 | |
Research Site | |
Kyoto-shi, Japan, 606-8507 | |
Research Site | |
Nagasaki-shi, Japan, 852-8501 | |
Research Site | |
Setagaya-ku, Japan, 157-8535 | |
Research Site | |
Tsukuba-shi, Japan, 305-8576 | |
Research Site | |
Yokohama-shi, Japan, 232 8555 | |
Poland | |
Research Site | |
Bydgoszcz, Poland, 85-048 | |
South Africa | |
Research Site | |
Parktown, South Africa, 2193 | |
Research Site | |
Soweto, South Africa, 2013 | |
Spain | |
Research Site | |
Barcelona, Spain, 8035 | |
Research Site | |
Granada, Spain, 18014 | |
Research Site | |
Madrid, Spain, 28041 | |
Research Site | |
Madrid, Spain, 28046 | |
Ukraine | |
Research Site | |
Dnipro, Ukraine, 49006 | |
Research Site | |
Kharkiv, Ukraine, 61075 | |
United Kingdom | |
Research Site | |
Nottingham, United Kingdom, NG7 2UH |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT04484935 |
Other Study ID Numbers: |
D5290C00008 |
First Posted: | July 24, 2020 Key Record Dates |
Last Update Posted: | November 14, 2022 |
Last Verified: | November 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AstraZeneca (AZ) disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AstraZeneca (AZ) are accepting requests for Individual Participant Data (IPD), but this does not mean all requests will be shared. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
Access Criteria: | When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
LRTI by RSV infection |
Respiratory Syncytial Virus Infections Infections Pneumovirus Infections Paramyxoviridae Infections |
Mononegavirales Infections RNA Virus Infections Virus Diseases |